You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Morten Beck Jorgensen

Managing Director, Financial Investments at Novo Holding A/S
Overview
Relationships
In The News
Paths
Education
Career History

Morten Beck Jorgensen

Managing Director, Financial Investments at Novo Holding A/S

Overview

Number of Relationships
This person is connected to 242 people.

Relationships See Details


Former Chief Financial Officer at Novo Holding A/S

Partner, Seed Investments at Novo Holding A/S

Professional at Novozymes Biotech, Inc.

Head of People & Organisation People & Organisaton at Novo Holding A/S

Managing Partner NOVO Ventures at Novo Holding A/S

Venture Partner NOVO Ventures at Novo Holding A/S

Senior Partner NOVO Ventures at Novo Holding A/S

Senior Director, Financial Investments at Novo Holding A/S

Operations Manager NOVO Ventures at Novo Holding A/S

Chief Financial Officer, Finance & Operations at Novo Holding A/S
See 232 more listings with RelSci Professional.

In The News See More

PR Newswire
March 5, 2013
PR Newswire
March 5, 2013
PR Newswire
March 5, 2013

Paths to Morten Beck Jorgensen

Morten Beck Jorgensen
You
Connections via Relationship Science
Morten Beck Jorgensen
Sync your contacts to see how you can connect with Morten Beck Jorgensen.

Educational Background

 
Class of 1997 
Aarhus University is a school in Aarhus.
MS Finance 
Aarhus School of Business is a school in Aarhus.

Career History

Managing Director, Financial Investments
2005 - Current
Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation’s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.
Senior Investment Director
Tenure Unconfirmed
Novo is an active, long-term manager which aims to support sustainable partnerships through the advancement of life sciences, investing more than half of their capital in North American companies and the rest in Denmark and Europe. The firm invests across technologies, products and financial stages, including providing funds for embryonic start-ups in extraordinary situations.Novo makes typical equity investments of 1-15 million euros, focusing on investee companies with significant profit and growth potential within the following areas: products that diagnose, control, treat and prevent disease; biotechnology development and applications; instruments and medical devices; improvement of food, nutrition and health for humans and animals and development of sustainable solutions for the environment.The firm typically takes a minority position in their investee companies, seeking to provide value-adding support in areas such as intellectual property rights, scientific evaluation, strategic business development, licensing and collaborations and financing strategies through their extensive network and active participation on the board of directors. Their typical exit strategies include IPOs, trade sales and mergers.The financial investments of Novo A/S comprise a portfolio of well-diversified assets, including liquid and listed equities, Danish government and mortgage bonds and high-yielding credit and emerging markets bonds. The firm seeks to spread risk by diversifying the Novo Nordisk Foundation's assets and creating a pool of liquid reserves which can be used to support Novo Group companies.
Assistant Treasurer
2001 - 2005
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Professional
Prior
Nordea Markets, part of Nordea Bank AB, is a company headquartered in Helsinki, Denmark, focused on security brokers, dealers, and flotation companies.

Other Affiliations

Morten Beck Jorgensen is affiliated with Novo Holding A/S, Novo Ventures, Novo Nordisk A/S, Nordea Markets.

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial
Still not convinced? Check out our full listing of features here.